Elevated soluble LOX-1 predicts risk of first-time myocardial infarction
(2023) In Annals of Medicine 55(2).- Abstract
Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in... (More)
Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in baseline plasma. Results: Subjects in the highest tertile of sLOX-1 had an increased risk of myocardial infarction (hazard ratio (95% CI) 1.76 (1.40-2.21) as compared with those in the lowest tertile. The presence of cardiovascular risk factors was related to elevated sLOX-1, but the association between sLOX-1 and risk of myocardial infarction remained significant when adjusting for risk factors. Conclusions: In this prospective population study we found an association between elevated sLOX-1, the presence of carotid disease and the risk for first-time myocardial infarction. Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, this observation supports LOX-1 inhibition as a possible target for prevention of myocardial infarction.
(Less)
- author
- Schiopu, Alexandru LU ; Björkbacka, Harry LU ; Narasimhan, Gayathri LU ; Loong, Bi Juin LU ; Engström, Gunnar LU ; Melander, Olle LU ; Orho-Melander, Marju LU and Nilsson, Jan LU
- organization
-
- Cardiac Inflammation Research Group (research group)
- EXODIAB: Excellence of Diabetes Research in Sweden
- Cardiovascular Research - Cellular Metabolism and Inflammation (research group)
- Cardiovascular research - Immune regulation (research group)
- Cardiovascular Research - Matrix and Inflammation in Atherosclerosis (research group)
- Cardiovascular Research - Immunity and Atherosclerosis (research group)
- Cardiovascular Research - Epidemiology (research group)
- EpiHealth: Epidemiology for Health
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- Cardiovascular Research - Hypertension (research group)
- Diabetes - Cardiovascular Disease (research group)
- publishing date
- 2023
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- disease mechanisms, LOX-1, myocardial infarction, population cohort, risk prediction
- in
- Annals of Medicine
- volume
- 55
- issue
- 2
- article number
- 2296552
- publisher
- Taylor & Francis
- external identifiers
-
- pmid:38134912
- scopus:85180713323
- ISSN
- 0785-3890
- DOI
- 10.1080/07853890.2023.2296552
- language
- English
- LU publication?
- yes
- additional info
- Publisher Copyright: © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
- id
- 86a60f72-22c3-493e-a80f-8f8cc7202614
- date added to LUP
- 2024-02-05 10:02:33
- date last changed
- 2024-04-21 17:16:04
@article{86a60f72-22c3-493e-a80f-8f8cc7202614, abstract = {{<p>Background: There is an unmet clinical need for novel therapies addressing the residual risk in patients receiving guideline preventive therapy for coronary heart disease. Experimental studies have identified a pro-atherogenic role of the oxidized LDL receptor LOX-1. We investigated the association between circulating soluble LOX-1 (sLOX-1) and the risk for development of myocardial infarction. Methods: The study subjects (n = 4658) were part of the Malmö Diet and Cancer study. The baseline investigation was carried out 1991-1994 and the incidence of cardiovascular events monitored through national registers during a of 19.5 ± 4.9 years follow-up. sLOX-1 and other biomarkers were analyzed by proximity extension assay and ELISA in baseline plasma. Results: Subjects in the highest tertile of sLOX-1 had an increased risk of myocardial infarction (hazard ratio (95% CI) 1.76 (1.40-2.21) as compared with those in the lowest tertile. The presence of cardiovascular risk factors was related to elevated sLOX-1, but the association between sLOX-1 and risk of myocardial infarction remained significant when adjusting for risk factors. Conclusions: In this prospective population study we found an association between elevated sLOX-1, the presence of carotid disease and the risk for first-time myocardial infarction. Taken together with previous experimental findings of a pro-atherogenic role of LOX-1, this observation supports LOX-1 inhibition as a possible target for prevention of myocardial infarction.</p>}}, author = {{Schiopu, Alexandru and Björkbacka, Harry and Narasimhan, Gayathri and Loong, Bi Juin and Engström, Gunnar and Melander, Olle and Orho-Melander, Marju and Nilsson, Jan}}, issn = {{0785-3890}}, keywords = {{disease mechanisms; LOX-1; myocardial infarction; population cohort; risk prediction}}, language = {{eng}}, number = {{2}}, publisher = {{Taylor & Francis}}, series = {{Annals of Medicine}}, title = {{Elevated soluble LOX-1 predicts risk of first-time myocardial infarction}}, url = {{http://dx.doi.org/10.1080/07853890.2023.2296552}}, doi = {{10.1080/07853890.2023.2296552}}, volume = {{55}}, year = {{2023}}, }